Zacks Investment Research on MSN
OM stock gains on FDA clearance for next-gen Tablo dialysis system
Outset Medical, Inc. OM recently announced that its next-generation Tablo hemodialysis system has received 510(k) clearance, ...
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standardsSAN JOSE, Calif., Jan. 27, 2026 ...
SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced that its Tablo® Hemodialysis System has received the first-ever approval from the Centers for Medicare ...
Medical Device Network on MSN
Outset Medical secures FDA clearance for Tablo haemodialysis system
Outset Medical plans to begin shipping the updated platform during the second quarter of 2026.
Outset Medical announced today that it received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform.
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from ASN Kidney Week, Michael Aragon, MD, the chief medical officer of Outset Medical, ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from ASN Kidney Week, Michael Aragon, MD, the chief medical officer of Outset Medical, ...
SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug ...
After kicking off the year by shipping out a record number of its Tablo hemodialysis systems for at-home users, Outset Medical has brought those sales to a screeching halt. The California-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results